Combining GLP?1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Scoping Review and Expert Insights for Clinical Practice Utilizing the Nominal Group Technique / Carlos Esteban Builes Montaño ; Yepes Cortés, Carlos A. ; Cardenas Moreno, Isabel C. ; Daza Arnedo, Rodrigo ; Feriz Bonelo, Karen M. ; Yama Mosquera, Erica ; Ramirez Rincón, Alex H. ; Castillo Barrios, Gilberto A. ; Suarez Rodriguez, Andres F. ; Carreño Jiménez, Johanna  

Público ISBD Título : Combining GLP?1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Scoping Review and Expert Insights for Clinical Practice Utilizing the Nominal Group Technique Tipo de documento : documento electrónico Autores : Carlos Esteban Builes Montaño, Autor ; Yepes Cortés, Carlos A., Autor ; Cardenas Moreno, Isabel C., Autor ; Daza Arnedo, Rodrigo, Autor ; Feriz Bonelo, Karen M., Autor ; Yama Mosquera, Erica, Autor ; Ramirez Rincón, Alex H., Autor ; Castillo Barrios, Gilberto A., Autor ; Suarez Rodriguez, Andres F., Autor ; Carreño Jiménez, Johanna, Autor Fecha de publicación : 2025 Títulos uniformes : Diabetes Therapy Idioma : Inglés (eng) Palabras clave : Diabetes mellitus; Diabetes complications; Glucagon-like peptide 1 receptor agonists; Sodium-glucose cotransporter 2 inhibitors Resumen : Introduction Treating type 2 diabetes has shifted from a gluco-centric approach to broader cardio-renal-metabolic strategy, driven by the use of disease-modifying medications. Traditionally, diabetes management has relied on stepwise medication addition based on failures in glucose control. However, the benefits and risks of combining glucagon-like peptide-1 receptor agonists (GLP1-RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) remain inadequately understood. Methods This study conducted a scoping review to examine the available clinical research on the benefits and risks of combining GLP1-RAs and SGLT2is. Additionally, the nominal group technique was used to gather insights from medical experts from different areas regarding the combined therapy’s daily clinical use, concerns, and limitations. The review followed the guidelines outlined in the Joanna Briggs Institute Reviewer’s Manual and the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews). Result The final report includes 50 studies. The most common designs are observational studies. The median (IQR) number of patients across studies was 355 (1295). Studies reporting metabolic outcomes were the most common. The follow-up time ranges from 1.5 to 60 months. Although limited, the available evidence seems to support the combined use of GLP1-RAs and SGLT2is. The experts agreed that the underlying mechanisms appear synergistic rather than antagonistic for most outcomes. Conclusions Combining medical therapy is common in diabetes treatment and may occur naturally in everyday practice. Limited evidence suggests that combined SGLT2is/GLP1-RAs therapy can potentially improve most but not all outcomes. Quality evidence and better-defined outcomes are paramount to guide the selection of patients for combined therapy. Mención de responsabilidad : Carlos A. Yepes?Cortés · Isabel C. Cardenas?Moreno · Rodrigo Daza?Arnedo · Karen M. Feriz?Bonelo · Erica Yama?Mosquera · Alex H. Ramirez?Rincón · Gilberto A. Castillo?Barrios · Andres F. Suarez?Rodriguez · Johanna Carreño?Jiménez · Carlos E. Builes?Montaño Referencia : Diabetes Ther (2025) 16:813–849 DOI (Digital Object Identifier) : 10.1007/s13300-025-01722-x. Derechos de uso : CC BY-NC-ND En línea : https://link.springer.com/article/10.1007/s13300-025-01722-x Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Combining GLP?1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Scoping Review and Expert Insights for Clinical Practice Utilizing the Nominal Group Technique [documento electrónico] / Carlos Esteban Builes Montaño, Autor ; Yepes Cortés, Carlos A., Autor ; Cardenas Moreno, Isabel C., Autor ; Daza Arnedo, Rodrigo, Autor ; Feriz Bonelo, Karen M., Autor ; Yama Mosquera, Erica, Autor ; Ramirez Rincón, Alex H., Autor ; Castillo Barrios, Gilberto A., Autor ; Suarez Rodriguez, Andres F., Autor ; Carreño Jiménez, Johanna, Autor . - 2025. Obra : Diabetes Therapy Idioma : Inglés (eng) Palabras clave : Diabetes mellitus; Diabetes complications; Glucagon-like peptide 1 receptor agonists; Sodium-glucose cotransporter 2 inhibitors Resumen : Introduction Treating type 2 diabetes has shifted from a gluco-centric approach to broader cardio-renal-metabolic strategy, driven by the use of disease-modifying medications. Traditionally, diabetes management has relied on stepwise medication addition based on failures in glucose control. However, the benefits and risks of combining glucagon-like peptide-1 receptor agonists (GLP1-RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) remain inadequately understood. Methods This study conducted a scoping review to examine the available clinical research on the benefits and risks of combining GLP1-RAs and SGLT2is. Additionally, the nominal group technique was used to gather insights from medical experts from different areas regarding the combined therapy’s daily clinical use, concerns, and limitations. The review followed the guidelines outlined in the Joanna Briggs Institute Reviewer’s Manual and the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews). Result The final report includes 50 studies. The most common designs are observational studies. The median (IQR) number of patients across studies was 355 (1295). Studies reporting metabolic outcomes were the most common. The follow-up time ranges from 1.5 to 60 months. Although limited, the available evidence seems to support the combined use of GLP1-RAs and SGLT2is. The experts agreed that the underlying mechanisms appear synergistic rather than antagonistic for most outcomes. Conclusions Combining medical therapy is common in diabetes treatment and may occur naturally in everyday practice. Limited evidence suggests that combined SGLT2is/GLP1-RAs therapy can potentially improve most but not all outcomes. Quality evidence and better-defined outcomes are paramount to guide the selection of patients for combined therapy. Mención de responsabilidad : Carlos A. Yepes?Cortés · Isabel C. Cardenas?Moreno · Rodrigo Daza?Arnedo · Karen M. Feriz?Bonelo · Erica Yama?Mosquera · Alex H. Ramirez?Rincón · Gilberto A. Castillo?Barrios · Andres F. Suarez?Rodriguez · Johanna Carreño?Jiménez · Carlos E. Builes?Montaño Referencia : Diabetes Ther (2025) 16:813–849 DOI (Digital Object Identifier) : 10.1007/s13300-025-01722-x. Derechos de uso : CC BY-NC-ND En línea : https://link.springer.com/article/10.1007/s13300-025-01722-x Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD002356	AC-2025-039	Archivo digital	Producción Científica	Artículos científicos	Disponible

---

1 (1 - 1 / 1) Por página: 25 50 100 200